Royal Free Hospital, London
Engitix Therapeutics is seeking a Scientist skilled in cellular and molecular biology to contribute to our oncology target discovery and drug development projects. This is an exciting lab-based role in which you will use genomic and proteomic-based approaches to identify candidate drug targets using our novel extracellular matrix-based in vitro models. Using biochemical and molecular biology techniques, you will validate drug targets and novel therapeutic agents. Experience in mammalian cell culture, cell-based assays (for proliferation, apoptosis, target engagement), flow cytometry, immunofluorescence, immunohistochemistry, western blotting and qRT-PCR is highly desirable. Familiarity with the generation or analysis of large-scale, ‘omics-based datasets would be an advantage.
- PhD in cellular or molecular biology, molecular pharmacology or cancer genomics.
- Experience in mammalian cell culture, cell/molecular biology techniques.
- Able to plan and execute experiments independently.
- Previous experience in lab-based oncology research.
Engitix is developing a portfolio of programmes in fibrosis and solid tumours using its pioneering human extracellular matrix (ECM) drug discovery platform. The use of more physiologically relevant human in vitro models is transforming our ability to identify new targets, determine modes/mechanisms of action, and more accurately predict the efficacy of therapeutics candidates.
Now a transatlantic biotechnology company, Engitix was founded in July 2016 to commercialise cutting-edge research executed at the Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL). The Company is headquartered at the world-renowned Royal Free Hospital, London, UK with its wholly-owned US subsidiary Engitix, Inc, based in Cambridge, MA, US.
If you would like to apply for this position, please send a full CV along with a covering letter to email@example.com.